Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

15 December 2006

Volume 194, Number 12
The Journal of Infectious Diseases 2006;194:1686–1696
0022-1899/2006/19412-0010$15.00
DOI: 10.1086/508750
MAJOR ARTICLE

Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and Failure

Serena Spudich,1

Nicole Lollo,1

Teri Liegler,2

Steven G. Deeks,2 and

Richard W. Price1

Departments of 1Neurology and 2Medicine, San Francisco General Hospital, University of California, San Francisco

Objective.To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)–1 RNA levels and CSF inflammation.

Design.The study was a cross‐sectional analysis of 139 HIV‐1–infected subjects without active neurological disease, categorized as having successful therapy (plasma HIV‐1 RNA level 500 copies/mL), having failure of therapy (plasma HIV‐1 RNA level >500 copies/mL), or not receiving therapy. The control group consisted of 48 HIV‐negative subjects. CSF and plasma HIV‐1 RNA assays had a lower limit of quantification of 2.5 copies/mL. Genotypic resistance testing was performed on a subset of subjects.

Results.Of the 47 subjects with successful therapy, CSF HIV‐1 RNA levels were <2.5 copies/mL in 34 (72%). Only 1 had an HIV‐1 RNA level >500 copies/mL. Although plasma HIV‐1 RNA levels were similar in 35 subjects with failed therapy and 57 of those not receiving therapy ( ), CSF HIV‐1 RNA levels were at least 10‐fold lower in subjects with failed therapy ( ). This disproportionate effect of treatment on CSF HIV‐1 RNA levels was found across the range of plasma HIV‐1 RNA levels and was not explained by differences in levels of drug resistance in plasma or CSF. Therapy reduced CSF inflammation in both treated groups.

Conclusions.In our cohort, antiretroviral therapy had a greater effect on HIV‐1 RNA levels in CSF than in plasma and reduced intrathecal inflammation, even in the presence of drug resistance.

Received 11 April 2006; accepted 7 June 2006; electronically published 3 November 2006.

Reprints or correspondence: Dr. Serena S. Spudich, Neurology, Rm. 4M62, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110‐3518 ().

Cited by

Christina M Marra, Yu Zhao, David B Clifford, Scott Letendre, Scott Evans, Katherine Henry, Ronald J Ellis, Benigno Rodriguez, Robert W Coombs, Giovanni Schifitto, Justin C McArthur, Kevin Robertson. (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:11, 1359-1366
Online publication date: 1-Aug-2009.
CrossRef
Åsa Mellgren. (2008) Preventing brain damage in HIV infection. Future Neurology 3:5, 565-574
Online publication date: 1-Oct-2008.
CrossRef
Richard W. Price and Serena Spudich. (2008) Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection. The Journal of Infectious Diseases 197:s3, S294-S306
Online publication date: 15-May-2008.
Elizabeth Sinclair, Rollie Ronquillo, Nicole Lollo, Steven G Deeks, Peter Hunt, Constantin T Yiannoutsos, Serena Spudich, Richard W Price. (2008) Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:5, 544-552
Online publication date: 1-May-2008.
CrossRef
Aylin Yilmaz, Richard W Price, Serena Spudich, Dietmar Fuchs, Lars Hagberg, Magnus Gisslén. (2008) Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:2, 168-173
Online publication date: 1-Mar-2008.
CrossRef
Arvid Edén, Richard W. Price, Serena Spudich, Dietmar Fuchs, Lars Hagberg, and Magnus Gisslén. (2007) Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases 196:12, 1779-1783
Online publication date: 15-Dec-2007.
Scott L. Letendre, Geoffrey van den Brande, Ashwaq Hermes, Steven Paul Woods, Janis Durelle, Jennifer Marquie Beck, J. Allen McCutchan, Charles Okamoto, Ronald J. Ellis, and the HIV Neurobehavioral Research Center Group. (2007) Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid. Clinical Infectious Diseases 45:11, 1511-1517
Online publication date: 1-Dec-2007.
Justin C. McArthur and Scott L. Letendre. (2006) Is the Glass Three‐Quarters Full or One‐Quarter Empty?. The Journal of Infectious Diseases 194:12, 1628-1631
Online publication date: 15-Dec-2006.
  • Presented in part: 13th Conference on Retroviruses and Opportunistic Infections, Denver, 5–8 February 2006 (abstract E‐129).

    Potential conflicts of interest: none reported.

    Financial support: National Institutes of Health (grants R01 NS37660, R01 MH62701, R01 NS43103, K23 MH074466, P30 AI027763, and MO1 RR0008336).

Close Popup